Opinion

Video

Exploring Treatments for BCG-Unresponsive Intermediate-High Risk NMIBC

Expert urologist explores potential treatments for BCG-unresponsive intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC), including immune checkpoint inhibitors, oncolytic viral therapy, cytokine agonists, immunomodulators, and the recently approved drugs pembrolizumab and nogapendekin alfa inbakicept-pmln.

  1. Can you discuss some of the exploratory treatments for BCG‐unresponsive intermediate and high risk‐NMIBC? (eg. immune checkpoint inhibitors (ICI), oncolytic viral therapy, cytokine agonists, and other immunomodulators)
  2. BCG‐unresponsiveness (definition?)
    1. Include (recently) approved immunotherapies: pembrolizumab, nogapendekin alfa inbakicept-pmln
  3. Gene therapy: nadofaragene firadenovec
Related Videos
1 expert in this video
2 experts are featured in this series.
1 expert is featured in this series.
2 experts are featured in this series.
1 expert in this video
1 expert is featured in this series.
1 expert in this video
4 experts in this video
Related Content
Urologic surgeons successfully complete world’s first bladder transplant
May 19th 2025

Urologic surgeons successfully complete world’s first bladder transplant

Hannah Clarke
The bladder transplant procedure involved a collaboration between the University of California, Los Angeles and the University of Southern California.
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
May 17th 2025

Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

Amy M. Pearlman, MD Alex Tatem, MD
Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
Disitamab vedotin plus toripalimab extends PFS, OS in HER2-positive la/mUC
May 12th 2025

Disitamab vedotin plus toripalimab extends PFS, OS in HER2-positive la/mUC

Hannah Clarke
The phase 3 RC48-C016 trial met its primary end points.
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
Physical function and frailty measures offer distinct insights in patients with bladder cancer
May 7th 2025

Physical function and frailty measures offer distinct insights in patients with bladder cancer

Hannah Clarke
Data showed that physical function and self-reported frailty assessments were poorly correlated.
FDA to host advisory committee meeting on UGN-102 for NMIBC
May 7th 2025

FDA to host advisory committee meeting on UGN-102 for NMIBC

Hannah Clarke
The Oncologic Drugs Advisory Committee meeting is scheduled for May 21, 2025.
© 2025 MJH Life Sciences

All rights reserved.